WO2023002409 - COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES
National phase entry:
Publication Number
WO/2023/002409
Publication Date
26.01.2023
International Application No.
PCT/IB2022/056712
International Filing Date
20.07.2022
Title **
[English]
COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES
[French]
COMPOSÉS ET COMPOSITIONS POUR LE TRAITEMENT DE MALADIES ASSOCIÉES AU CORONAVIRUS
Applicants **
NOVARTIS AG
Lichtstrasse 35
4056 Basel, CH
Inventors
BAO, Denghui
c/o Suzhou Novartis Technical Development Co., Ltd.
#18 Tonglian Road Riverside Industrial Park Changshu Economic Development Zone
Changshu, Jiangsu 215537, CN
GUO, Fengfeng
c/o Suzhou Novartis Technical Development Co., Ltd.
#18 Tonglian Road Riverside Industrial Park Changshu Economic Development Zone
Changshu, Jiangsu 215537, CN
HESSE, Matthew James
c/o Novartis Institutes for BioMedical Research, Inc.
5959 Horton Street, 9th Floor
Emeryville, California 94608, US
HORNAK, Viktor
c/o Novartis Institutes for Biomedical Research, Inc.
250 Massachusetts Avenue
Cambridge, Massachusetts 02139, US
JOSEPH, Sajan
c/o Novartis Institutes for BioMedical Research, Inc.
250 Massachusetts Avenue
Cambridge, Massachusetts 02139, US
KIRRANE JR., Thomas Martin
c/o Novartis Institutes for BioMedical Research, Inc.
5959 Horton Street, 9th Floor
Emeryville, California 94608, US
LIU, Bo
c/o China Novartis Institutes for BioMedical Research Co., Ltd.
4218 Jinke Road
Zhangjiang Hi-Tech Park
Pudong New Area, Shanghai 201203, CN
LIN, Haiyao
c/o Suzhou Novartis Technical Development Co., Ltd.
#18 Tonglian Road Riverside Industrial Park Changshu Economic Development Zone
Changshu, Jiangsu 215537, CN
MIAO, Yanan
c/o Suzhou Novartis Technical Development Co., Ltd.
#18 Tonglian Road Riverside Industrial Park Changshu
Economic Development Zone
Changshu, Jiangsu 215537, CN
MOSER, Heinz Ernst
c/o Novartis Institutes for BioMedical Research, Inc.
5959 Horton Street, 9th Floor
Emeryville, California 94608, US
PAPILLON, Julien
c/o Novartis Institutes for BioMedical Research, Inc.
250 Massachusetts Avenue,
Cambridge, Massachusetts 02139, US
QU, Yang
c/o Suzhou Novartis Technical Development Co., Ltd.
#18 Tonglian Road Riverside Industrial Park Changshu Economic Development Zone
Changshu, Jiangsu 215537, CN
SHI, Lei
c/o Suzhou Novartis Technical Development Co., Ltd.
#18 Tonglian Road Riverside Industrial Park Changshu Economic Development Zone
Changshu, Jiangsu 215537, CN
YUAN, Jun
c/o Novartis Institutes for BioMedical Research, Inc.
250 Massachusetts Avenue
Cambridge, Massachusetts 02139, US
ZHANG, Teng
c/o China Novartis Institutes for BioMedical Research Co., Ltd.
4218 Jinke Road
Zhangjiang Hi-Tech Park
Pudong New Area, Shanghai 201203, CN
Priority Data
63/224,793
22.07.2021
US
63/289,009
13.12.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 5512 | |
| EPO | Filing, Examination | 39278 | |
| Japan | Filing | 588 | |
| South Korea | Filing | 606 | |
| USA | Filing, Examination | 42010 |
Total: 87994 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Provided herein are compounds and compositions for treating, managing or preventing coronaviral related diseases. In particular, provided herein are compounds which are inhibitors of SARS-CoV-2 main protease (Mpro), pharmaceutical compositions comprising such compounds, method for synthesizing such compounds and methods of using such compounds and compositions for the treatment, management or prevention of coronaviral related diseases.[French]
L'invention concerne des composés et des compositions pour le traitement, la gestion ou la prévention de maladies associées au coronavirus. En particulier, l'invention concerne des composés qui sont des inhibiteurs de la protéase principale du SARS-CoV-2 (Mpro), des compositions pharmaceutiques comprenant de tels composés, un procédé de synthèse de tels composés et des procédés d'utilisation de ces composés et de ces compositions pour le traitement, la gestion ou la prévention de maladies associées au coronavirus.